Breaking Barriers
to Better Cancer Treatment


The team at Incendia recognizes that cancer cells create a hostile microenvironment to privilege their own survival at the expense of the host tissue.

Incendia’s approach is to attack the structural and biochemical underpinnings of this tumor microenvironment to enable host immune cells and Immuno-oncology therapeutics to reach their target.

Our Team

We are scientists, drug developers, clinicians, pathologists, bioinformaticians, engineers, innovators, and cancer warriors redefining the treatment landscape for patients with recalcitrant cancers.


Wendye Robbins

Wendye R. Robbins, MD

President & Chief Executive Officer

Joesph Paul Elder

Joseph Paul Eder, MD

Chief Medical Officer

Guy Travis Clifton

Guy Travis Clifton, MD

Head of Clinical Sciences & Co-Founder

Laura Dillon

Laura Dillon, PhD

VP, Translational Medicine & Bioinformatics

Thomas Schürpf

Thomas Schürpf, PhD

VP, Head of Development

Erin McDonald

Erin McDonald

Head of Operations

Tom McCoughtry

Tom McCaughtry, PhD

VP, Head of Research

Jeff Janotka

Jeff Janotka

VP, Clinical Operations

Susan G. Macdonald

Susan G. Macdonald, PhD

VP, R&D Strategy and Program Management

Board of Directors

Michael Kauffman

Michael Kauffman, MD

Independent, Chairman of the Board

Sakae Asanuma

Sakae Asanuma

CFA, MBA, President & CEO

Steve Liapis

Steve Liapis


Christopher O’Donnell

Christopher O’Donnell, PhD

Vice President, WRDM / Partner

Wendye Robbins

Wendye R. Robbins, MD

President & Chief Executive Officer

Advisory Board

Zhiqiang An, PhD

Dir. Therapeutics Inst. U Texas Health Science Center

Michael Cecchini, MD

GI Oncologist, Early Drug Development Program, Yale

Hervé Fridman, MD PhD

Former Head of the IO Center Cordeliers, Paris

Pamela Munster, MD

Director, Early Phase Clinical Trials Unit UCSF

Rong Li, PhD

Chair Mol Med, George Washington U

Paolo Provenzano, PhD

Dept. of Biomed Engineering, U Minnesota & Bioinformatics

Ellen Puré, A.B., PhD

Chair Dept Biomedical Sciences and Dir. Penn Vet Cancer Ctr

Mace Rothenberg, MD

Former CMO & CDO Oncology Pfizer



alexandria logo
breakout ventures logo
creacion logo
kdt ventures logo
northpond logo
parkwest logo
pfizer logo
s32 logo
taiho logo
tekla logo

Our Pipeline

Our pipeline and drug discovery engine leverage an unprecedented approach for striking at immune-excluded tumors often found in recalcitrant cancers.

* A first-in-human study of PRTH-101 in patients with advanced or metastatic solid tumors. Visit for detail, NCT05753722.

Our Science

Incendia is currently running a phase 1 clinical trial evaluating the safety, biologic, and clinical impact of PRTH-101 alone and in combination with PD-1 inhibition (NCT05753722).

PRTH-101 is a monoclonal antibody that binds to and inhibits Discoidin Domain Receptor 1 (DDR1). DDR1 is a collagen receptor that is highly expressed by cancer cells in multiple tumor types. Higher levels of DDR1 expression are associated with increased tumor invasiveness, chemoresistance, and worse outcomes in cancer. DDR1 promotes collagen fiber alignment, creating a physical barrier that prevents immune cells from interacting with and attacking tumor cells. Preclinical studies have shown that blocking DDR1 with PRTH-101 disrupts the tumor cell-induced collagen fiber alignment, thus creating gaps in this barrier and allowing T cells to enter and attack the tumor cells. Thus, PRTH-101 represents a unique approach to stimulating immune-based antitumor activity.

Additionally, addressing aligned collagen with PRTH-101 may allow established cancer therapeutics to work more effectively. Gaps in the collagen barrier may allow modified T cell therapies to enter solid tumors more easily. It may decrease tumor bed oncotic pressure allowing the diffusion of chemotherapies into the tumor at higher concentrations. Similarly, PRTH-101 may decrease hypoxia in the tumor microenvironment allowing radiation to work more effectively.

Join Our Team

Incendia Therapeutics is a precision oncology biotech company dedicated to reprogramming the tumor microenvironment with the express intent of bringing recalcitrant cancers into submission. Our pipeline and drug discovery engine leverage an unprecedented approach for striking at immune-excluded tumors often found in recalcitrant cancers. Come join our dynamic team!

There are no current opportunities, please check back.

Our Mission

Incendia Therapeutics was created to serve cancer patients who are the most in need of novel therapeutics. Everything we do is guided by caring for and doing the right thing for those patients.

Our Values

Incendia team

Incendia team